The RELIEVE trial assesses remibrutinib's efficacy and safety in generalized myasthenia gravis, involving 180 participants in a 6-month double-blind study. Remibrutinib has shown a positive safety ...
As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average of 27.3 pounds in the first of two pivotal trials, queuing up plans for a ...
- 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy, and stabilization of estimated ...
(RTTNews) - Shares of Inhibikase Therapeutics, Inc. (IKT) are up 12% at $1.72 in pre-market trading, after the company announced progress on its lead program alongside a major financing deal.
On-track progress for the New Drug Application (NDA) for paltusotine, with a PDUFA target action date set for September 25, 2025, indicating strong engagement with the FDA. Marketing authorization ...
Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, ...
AstraZeneca's aldosterone synthase inhibitor baxdrostat reduced blood pressure by 14 mmHg over 12 weeks, the pharma has said in a first look at the data from a key phase 3 win. Baxdrostat has a ...
Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results